Cargando…
Optimized LC-MS/MS quantification of tuberculosis drug candidate macozinone (PBTZ169), its dearomatized Meisenheimer Complex and other metabolites, in human plasma and urine
Tuberculosis, and especially multidrug-resistant tuberculosis (MDR-TB), is a major global health threat which emphasizes the need to develop new agents to improve and shorten treatment of this difficult-to-manage infectious disease. Among the new agents, macozinone (PBTZ169) is one of the most promi...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883661/ https://www.ncbi.nlm.nih.gov/pubmed/36563654 http://dx.doi.org/10.1016/j.jchromb.2022.123555 |
_version_ | 1784879552511606784 |
---|---|
author | Desfontaine, Vincent Guinchard, Sylvie Marques, Sara Vocat, Anthony Moulfi, Farizade Versace, François Huser-Pitteloud, Jeff Ivanyuk, Anton Bardinet, Carine Makarov, Vadim Ryabova, Olga André, Pascal Prod'Hom, Sylvain Chtioui, Haithem Buclin, Thierry Cole, Stewart T. Decosterd, Laurent |
author_facet | Desfontaine, Vincent Guinchard, Sylvie Marques, Sara Vocat, Anthony Moulfi, Farizade Versace, François Huser-Pitteloud, Jeff Ivanyuk, Anton Bardinet, Carine Makarov, Vadim Ryabova, Olga André, Pascal Prod'Hom, Sylvain Chtioui, Haithem Buclin, Thierry Cole, Stewart T. Decosterd, Laurent |
author_sort | Desfontaine, Vincent |
collection | PubMed |
description | Tuberculosis, and especially multidrug-resistant tuberculosis (MDR-TB), is a major global health threat which emphasizes the need to develop new agents to improve and shorten treatment of this difficult-to-manage infectious disease. Among the new agents, macozinone (PBTZ169) is one of the most promising candidates, showing extraordinary potency in vitro and in murine models against drug-susceptible and drug-resistant Mycobacterium tuberculosis. A previous analytical method using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) was developed by our group to support phase I clinical trials of PBTZ169. These plasma sample analyses revealed the presence of several additional metabolites among which the most prominent was H(2)PBTZ, a reduced species obtained by dearomatization of macozinone, one of the first examples of Meisenheimer Complex (MC) metabolites identified in mammals. Identification of these new metabolites required the optimization of our original method for enhancing the selectivity between isobaric metabolites as well as for ensuring optimal stability for H(2)PBTZ analyses. Sample preparation methods were also developed for plasma and urine, followed by extensive quantitative validation in accordance with international bioanalytical method recommendations, which include selectivity, linearity, qualitative and quantitative matrix effect, trueness, precision and the establishment of accuracy profiles using β-expectation tolerance intervals for known and newer analytes. The newly optimized methods have been applied in a subsequent Phase Ib clinical trial conducted in our University Hospital with healthy subjects. H(2)PBTZ was found to be the most abundant species circulating in plasma, underscoring the importance of measuring accurately and precisely this unprecedented metabolite. Low concentrations were found in urine for all monitored analytes, suggesting extensive metabolism before renal excretion. |
format | Online Article Text |
id | pubmed-9883661 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-98836612023-01-31 Optimized LC-MS/MS quantification of tuberculosis drug candidate macozinone (PBTZ169), its dearomatized Meisenheimer Complex and other metabolites, in human plasma and urine Desfontaine, Vincent Guinchard, Sylvie Marques, Sara Vocat, Anthony Moulfi, Farizade Versace, François Huser-Pitteloud, Jeff Ivanyuk, Anton Bardinet, Carine Makarov, Vadim Ryabova, Olga André, Pascal Prod'Hom, Sylvain Chtioui, Haithem Buclin, Thierry Cole, Stewart T. Decosterd, Laurent J Chromatogr B Analyt Technol Biomed Life Sci Article Tuberculosis, and especially multidrug-resistant tuberculosis (MDR-TB), is a major global health threat which emphasizes the need to develop new agents to improve and shorten treatment of this difficult-to-manage infectious disease. Among the new agents, macozinone (PBTZ169) is one of the most promising candidates, showing extraordinary potency in vitro and in murine models against drug-susceptible and drug-resistant Mycobacterium tuberculosis. A previous analytical method using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) was developed by our group to support phase I clinical trials of PBTZ169. These plasma sample analyses revealed the presence of several additional metabolites among which the most prominent was H(2)PBTZ, a reduced species obtained by dearomatization of macozinone, one of the first examples of Meisenheimer Complex (MC) metabolites identified in mammals. Identification of these new metabolites required the optimization of our original method for enhancing the selectivity between isobaric metabolites as well as for ensuring optimal stability for H(2)PBTZ analyses. Sample preparation methods were also developed for plasma and urine, followed by extensive quantitative validation in accordance with international bioanalytical method recommendations, which include selectivity, linearity, qualitative and quantitative matrix effect, trueness, precision and the establishment of accuracy profiles using β-expectation tolerance intervals for known and newer analytes. The newly optimized methods have been applied in a subsequent Phase Ib clinical trial conducted in our University Hospital with healthy subjects. H(2)PBTZ was found to be the most abundant species circulating in plasma, underscoring the importance of measuring accurately and precisely this unprecedented metabolite. Low concentrations were found in urine for all monitored analytes, suggesting extensive metabolism before renal excretion. Elsevier 2023-01-15 /pmc/articles/PMC9883661/ /pubmed/36563654 http://dx.doi.org/10.1016/j.jchromb.2022.123555 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Desfontaine, Vincent Guinchard, Sylvie Marques, Sara Vocat, Anthony Moulfi, Farizade Versace, François Huser-Pitteloud, Jeff Ivanyuk, Anton Bardinet, Carine Makarov, Vadim Ryabova, Olga André, Pascal Prod'Hom, Sylvain Chtioui, Haithem Buclin, Thierry Cole, Stewart T. Decosterd, Laurent Optimized LC-MS/MS quantification of tuberculosis drug candidate macozinone (PBTZ169), its dearomatized Meisenheimer Complex and other metabolites, in human plasma and urine |
title | Optimized LC-MS/MS quantification of tuberculosis drug candidate macozinone (PBTZ169), its dearomatized Meisenheimer Complex and other metabolites, in human plasma and urine |
title_full | Optimized LC-MS/MS quantification of tuberculosis drug candidate macozinone (PBTZ169), its dearomatized Meisenheimer Complex and other metabolites, in human plasma and urine |
title_fullStr | Optimized LC-MS/MS quantification of tuberculosis drug candidate macozinone (PBTZ169), its dearomatized Meisenheimer Complex and other metabolites, in human plasma and urine |
title_full_unstemmed | Optimized LC-MS/MS quantification of tuberculosis drug candidate macozinone (PBTZ169), its dearomatized Meisenheimer Complex and other metabolites, in human plasma and urine |
title_short | Optimized LC-MS/MS quantification of tuberculosis drug candidate macozinone (PBTZ169), its dearomatized Meisenheimer Complex and other metabolites, in human plasma and urine |
title_sort | optimized lc-ms/ms quantification of tuberculosis drug candidate macozinone (pbtz169), its dearomatized meisenheimer complex and other metabolites, in human plasma and urine |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883661/ https://www.ncbi.nlm.nih.gov/pubmed/36563654 http://dx.doi.org/10.1016/j.jchromb.2022.123555 |
work_keys_str_mv | AT desfontainevincent optimizedlcmsmsquantificationoftuberculosisdrugcandidatemacozinonepbtz169itsdearomatizedmeisenheimercomplexandothermetabolitesinhumanplasmaandurine AT guinchardsylvie optimizedlcmsmsquantificationoftuberculosisdrugcandidatemacozinonepbtz169itsdearomatizedmeisenheimercomplexandothermetabolitesinhumanplasmaandurine AT marquessara optimizedlcmsmsquantificationoftuberculosisdrugcandidatemacozinonepbtz169itsdearomatizedmeisenheimercomplexandothermetabolitesinhumanplasmaandurine AT vocatanthony optimizedlcmsmsquantificationoftuberculosisdrugcandidatemacozinonepbtz169itsdearomatizedmeisenheimercomplexandothermetabolitesinhumanplasmaandurine AT moulfifarizade optimizedlcmsmsquantificationoftuberculosisdrugcandidatemacozinonepbtz169itsdearomatizedmeisenheimercomplexandothermetabolitesinhumanplasmaandurine AT versacefrancois optimizedlcmsmsquantificationoftuberculosisdrugcandidatemacozinonepbtz169itsdearomatizedmeisenheimercomplexandothermetabolitesinhumanplasmaandurine AT huserpitteloudjeff optimizedlcmsmsquantificationoftuberculosisdrugcandidatemacozinonepbtz169itsdearomatizedmeisenheimercomplexandothermetabolitesinhumanplasmaandurine AT ivanyukanton optimizedlcmsmsquantificationoftuberculosisdrugcandidatemacozinonepbtz169itsdearomatizedmeisenheimercomplexandothermetabolitesinhumanplasmaandurine AT bardinetcarine optimizedlcmsmsquantificationoftuberculosisdrugcandidatemacozinonepbtz169itsdearomatizedmeisenheimercomplexandothermetabolitesinhumanplasmaandurine AT makarovvadim optimizedlcmsmsquantificationoftuberculosisdrugcandidatemacozinonepbtz169itsdearomatizedmeisenheimercomplexandothermetabolitesinhumanplasmaandurine AT ryabovaolga optimizedlcmsmsquantificationoftuberculosisdrugcandidatemacozinonepbtz169itsdearomatizedmeisenheimercomplexandothermetabolitesinhumanplasmaandurine AT andrepascal optimizedlcmsmsquantificationoftuberculosisdrugcandidatemacozinonepbtz169itsdearomatizedmeisenheimercomplexandothermetabolitesinhumanplasmaandurine AT prodhomsylvain optimizedlcmsmsquantificationoftuberculosisdrugcandidatemacozinonepbtz169itsdearomatizedmeisenheimercomplexandothermetabolitesinhumanplasmaandurine AT chtiouihaithem optimizedlcmsmsquantificationoftuberculosisdrugcandidatemacozinonepbtz169itsdearomatizedmeisenheimercomplexandothermetabolitesinhumanplasmaandurine AT buclinthierry optimizedlcmsmsquantificationoftuberculosisdrugcandidatemacozinonepbtz169itsdearomatizedmeisenheimercomplexandothermetabolitesinhumanplasmaandurine AT colestewartt optimizedlcmsmsquantificationoftuberculosisdrugcandidatemacozinonepbtz169itsdearomatizedmeisenheimercomplexandothermetabolitesinhumanplasmaandurine AT decosterdlaurent optimizedlcmsmsquantificationoftuberculosisdrugcandidatemacozinonepbtz169itsdearomatizedmeisenheimercomplexandothermetabolitesinhumanplasmaandurine |